ArticlePlanta medica2026
Selection of Promising Candidates for Herbal Veterinary Medicinal Products: A Strategic Approach.
Article in Planta medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Abstract: The growing urgency to reduce antimicrobial and antiparasitic use in livestock has renewed scientific interest in medicinal plants as sustainable components of veterinary healthcare. However, the absence of a dedicated regulatory framework for herbal veterinary medicinal products (HVMPs) in the European Union continues to hinder their wider application. Abstract: The need for a science-based, multi-criteria framework to identify medicinal plant species as sources of active substances of herbal origin, with the highest potential for future inclusion in a dedicated EU registration pathway for HVMPs, resulted in the establishment of a multidisciplinary expert panel. The panel evaluated over 100 medicinal plant species with documented veterinary application, using a structured scoring system integrating regulatory, pharmacopoeial, toxicological, and sustainability sources. These included regulations and documents related to veterinary, pharmaceutical, food, and feed data, as well as considerations for conservation. Weighted scores reflecting all these aspects were applied to rank the species. Abstract: The assessment resulted in the creation of List A, which contains the most promising candidates for future HVMPs, and List B, which compiles plant species whose simplified registration is currently not considered a priority or is not advisable based on the available data. Eighty-three species received positive overall scores. These medicinal plants demonstrate strong regulatory recognition, pharmacopoeial inclusion, and well-documented safety profiles, highlighting their suitability for evidence-based veterinary use. Abstract: The proposed framework offers a clear, reproducible method for prioritizing botanical species for regulatory consideration as HVMPs. It supports EU initiatives to enhance sustainable animal health, antimicrobial stewardship, and innovation in veterinary phytotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.